Tibotec and Bristol-Myers Team Up to Battle Hepatitis C

Share

Follow Us

Print this page

Bristol-Myers inks research deal with Tibotec for Daclatasvir

PBR Staff Writer

Published 05 December 2011

Bristol-Myers Squibb Company has entered into a clinical collaboration agreement with Sweden-based Medivir’s development partner, Tibotec Pharmaceuticals for Phase II combination study in patients with chronic hepatitis C virus (HCV).

The collaboration is intended to evaluate the utility of Daclatasvir (BMS-790052), Bristol-Myers Squibb’s investigational NS5A replication complex inhibitor, along with Tibotec Pharmaceuticals’ NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C.

Continue reading this entire article:
http://contractresearch.pharmaceutical-business-review.com/news/bristol-myers-inks-research-deal-with-tibotec-for-daclatasvir-051211

Download Our Free Reports

Inside you'll discover:

• Things You May Not Know About Hepatitis C
• 7 Liver Detox SUPER Foods Your Doctor Isn't Telling You About
• 5 Dangerous Foods That Will Wreak Havoc On Your Liver
• A free "Mystery" Gift Valued at $9.99

Email address

Download Now

You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.